Turn interaction into intelligence! Don’t miss this chance to lead the industry with our free pharma-exclusive webinar!

ASH 2025 showed up with a clenched fist and never loosened it. Under the rallying call of ‘Fight 4 Hematology’, the meeting ...

Union Chimique Belge (UCB) has announced the release of new positive data regarding Bimzelx (bimekizumab) in moderate to ...

Over 50 million people across the US live with acne, a condition with no cure that often requires chronic treatment ...

While obstructive sleep apnea (OSA) affects approximately 32% of US adults—nearly 80 million people—it remains an "epidemic hiding in plain sight". Perhaps most staggering is that 90% of women with ...

Gastric cancer is the fifth highest cause of cancer deaths worldwide, with almost a million people diagnosed annually ...

McNamara’s Fallacy is the error of making decisions based solely on easily quantifiable data, while ignoring ...

With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — ...

Johnson & Johnson has announced that its Darzalex Faspro-based regimen (daratumumab and hyaluronidase, in combination with ...

Alzheimer’s disease (AD) continues to be one of the most challenging conditions facing patients, families and healthcare ...

Biogen’s litifilimab has received Breakthrough Therapy Designation from the US FDA to treat cutaneous lupus erythematosus ...

The current landscape The landscape of dementia clinical trials in Europe is focused on AD, the most common form of dementia.